TransCode Therapeutics Inc (RNAZ) Actualités

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary...

Form EFFECT - Notice of Effectiveness

Form D - Notice of Exempt Offering of Securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the...

Form 8-K - Current report

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology...

Form 8-K - Current report

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

TransCode Therapeutics Open Letter to Shareholders

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]